Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
41.90-0.09 (-0.21%)
At close: 04:00PM EDT
41.90 0.00 (0.00%)
After hours: 04:20PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-432,842
-432,842
-351,511
-225,334
-152,142
Depreciation & amortisation
5,627
5,627
4,903
2,731
397
Stock-based compensation
69,410
69,410
38,780
23,941
10,521
Change in working capital
16,113
16,113
28,064
15,541
17,707
Accounts payable
2,038
2,038
-763
7,278
1,417
Other working capital
-346,109
-346,109
-297,141
-189,049
-136,694
Other non-cash items
19,091
19,091
-6,874
672
2,445
Net cash provided by operating activities
-342,301
-342,301
-293,187
-178,546
-117,802
Cash flows from investing activities
Investments in property, plant and equipment
-3,808
-3,808
-3,954
-10,503
-18,892
Purchases of investments
-865,270
-865,270
-887,737
-425,158
0
Sales/maturities of investments
942,800
942,800
502,857
0
-
Net cash used for investing activities
73,722
73,722
-388,834
-435,661
-18,892
Cash flows from financing activities
Common stock issued
498,944
498,944
238,263
328,251
0
Other financing activities
31,111
31,111
37,102
30,895
440,835
Net cash used provided by (used for) financing activities
548,616
548,616
623,191
423,602
440,835
Net change in cash
280,037
280,037
-58,830
-190,605
304,141
Cash at beginning of period
138,388
138,388
197,218
387,823
83,682
Cash at end of period
418,425
418,425
138,388
197,218
387,823
Free cash flow
Operating cash flow
-342,301
-342,301
-293,187
-178,546
-117,802
Capital expenditure
-3,808
-3,808
-3,954
-10,503
-18,892
Free cash flow
-346,109
-346,109
-297,141
-189,049
-136,694